Swiss National Bank C4 Therapeutics, Inc. Transaction History

Swiss National Bank

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$3.1 - $9.02 $26,970 - $78,474	-8,700 Reduced 10.53%	73,900 $232,000
Q4 2022 Feb 08, 2023	BUY	$5.42 - $10.24 $11,924 - $22,528	2,200 Added 2.74%	82,600 $487,000
Q2 2022 Aug 09, 2022	BUY	$5.06 - $26.46 $261,095 - $1.37 Million	51,600 Added 179.17%	80,400 $606,000
Q1 2022 May 09, 2022	BUY	$19.99 - $33.23 $41,979 - $69,783	2,100 Added 7.87%	28,800 $699,000
Q4 2021 Feb 08, 2022	BUY	$29.39 - $46.86 $85,231 - $135,894	2,900 Added 12.18%	26,700 $860,000
Q2 2021 Aug 06, 2021	BUY	$30.39 - $42.18 $723,282 - $1 Million	23,800 New	23,800 $901,000

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $178M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.